BRPI0510593A - composições para afetar a perda de peso - Google Patents

composições para afetar a perda de peso

Info

Publication number
BRPI0510593A
BRPI0510593A BRPI0510593-5A BRPI0510593A BRPI0510593A BR PI0510593 A BRPI0510593 A BR PI0510593A BR PI0510593 A BRPI0510593 A BR PI0510593A BR PI0510593 A BRPI0510593 A BR PI0510593A
Authority
BR
Brazil
Prior art keywords
weight loss
compositions
individual
compound
affect weight
Prior art date
Application number
BRPI0510593-5A
Other languages
English (en)
Inventor
Ranga Krishnan
Kishore Gadde
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of BRPI0510593A publication Critical patent/BRPI0510593A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

COMPOSIçõES PARA AFETAR A PERDA DE PESO. São descritas composições para afetar a perda de peso compreendendo um primeiro composto e um segundo composto, onde o primeiro composto é um antidiabético e o segundo composto é um anticonvulsivo. Também são descritos métodos de afetar a perda de peso, aumentando o gasto de energia, aumentando a sociedade em um indivíduo, ou suprimindo o apetite de um indivíduo, compreendendo a identificação de um indivíduo que necessita do mesmo e tratando esse indivíduo com um antidiabético ou um anticonvulsivo.
BRPI0510593-5A 2004-05-03 2005-04-27 composições para afetar a perda de peso BRPI0510593A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56792204P 2004-05-03 2004-05-03
PCT/US2005/014629 WO2005110405A1 (en) 2004-05-03 2005-04-27 Compositions for affecting weight loss

Publications (1)

Publication Number Publication Date
BRPI0510593A true BRPI0510593A (pt) 2007-11-20

Family

ID=34967494

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510593-5A BRPI0510593A (pt) 2004-05-03 2005-04-27 composições para afetar a perda de peso

Country Status (13)

Country Link
US (1) US20050277579A1 (pt)
EP (1) EP1748776A1 (pt)
JP (1) JP2007536229A (pt)
CN (1) CN1968692A (pt)
AR (1) AR048771A1 (pt)
AU (1) AU2005244151A1 (pt)
BR (1) BRPI0510593A (pt)
CA (1) CA2565154A1 (pt)
IL (1) IL178977A0 (pt)
MX (1) MXPA06012685A (pt)
RU (1) RU2006139930A (pt)
TW (1) TW200536553A (pt)
WO (1) WO2005110405A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4545584B2 (ja) * 2002-05-17 2010-09-15 デューク ユニバーシティ 肥満を治療するための方法
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
RU2350327C2 (ru) * 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7429580B2 (en) 2004-01-13 2008-09-30 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
EP1991243A1 (en) * 2006-03-08 2008-11-19 HHC Formulations Ltd. Compositions and methods for increasing adipose metabolism, lipolysis or lipolytic metabolism via thermogenesis
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2007141018A1 (en) * 2006-06-08 2007-12-13 Schwarz Pharma Ag Therapeutic combination for painful medical conditions
ES2531118T5 (es) 2006-06-15 2022-06-14 Ucb Pharma Gmbh Composición farmacéutica que comprende lacosamida y levetiracetamo para uso en el tratamiento de la epilepsia
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US8293911B2 (en) * 2006-08-23 2012-10-23 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
EP2033656A1 (en) * 2007-09-04 2009-03-11 Stichting Top Institute Food and Nutrition Satiety-modulating compositions for oral application
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CA2668885C (en) 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
TW201811315A (zh) 2006-11-09 2018-04-01 美商歐瑞根治療有限公司 層狀醫藥調配物
WO2008066900A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
ES2753141T3 (es) * 2009-11-03 2020-04-07 Lupin Ltd Formulación de liberación modificada de lacosamida
BR112012011237A2 (pt) 2009-11-13 2019-09-24 Univ Tokyo agente terapêutico e profilático para diabetes
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
EP2621282B1 (en) * 2010-09-28 2020-04-15 The Regents of The University of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
WO2012054816A2 (en) * 2010-10-22 2012-04-26 Mitokine Bioscience, Llc Methods of delaying and treating diabetes
PT3730132T (pt) 2012-06-06 2022-08-16 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
CN109069480A (zh) 2015-12-30 2018-12-21 阿达玛斯医药公司 用于治疗与癫痫相关的病症的方法和组合物
WO2020047603A1 (en) * 2018-09-06 2020-03-12 Monash University Method of treating a sleep breathing disorder
WO2021029813A1 (en) * 2019-08-09 2021-02-18 Diamyd Medical Ab Preventing and treating hypoglycemia
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CA3155812A1 (en) 2019-11-08 2021-05-14 Cynthia Louise HARDEN Methods of treating depressive disorders
CN116847843A (zh) 2021-02-09 2023-10-03 泽农医药公司 用于治疗快感缺乏的电压门控的钾通道开放剂

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8800823A (nl) * 1987-04-10 1988-11-01 Sandoz Ag Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten.
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5713488A (en) * 1996-01-24 1998-02-03 Farrugia; John V. Condom dispenser
CA2220768A1 (en) * 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds
EP0915697B1 (en) * 1996-06-28 2002-09-18 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
AU750808B2 (en) * 1997-10-03 2002-07-25 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
US6262049B1 (en) * 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
IL137346A0 (en) * 1998-01-21 2001-07-24 Glaxo Group Ltd Pharmaceutically active morpholinol
US6048322A (en) * 1998-04-15 2000-04-11 Kushida; Clete Morphometric measurement tool
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US20030144174A1 (en) * 1998-12-09 2003-07-31 Miles B. Brennan Methods for identifying compounds useful for the regulation of body weight and associated conditions
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
MXPA01009893A (es) * 1999-04-01 2003-07-28 Esperion Therapeutics Inc Compuestos con eter, composiciones y usos de estos.
PL350924A1 (en) * 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
US6420369B1 (en) * 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
US7056890B2 (en) * 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
CA2397726A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
CA2403252A1 (en) * 2000-03-15 2001-09-20 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
PT1326630E (pt) * 2000-09-18 2008-09-02 Sanos Bioscience As Utilização de péptidos glp-2
ATE334718T1 (de) * 2000-10-30 2006-08-15 Ortho Mcneil Pharm Inc Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
US20030087896A1 (en) * 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US6481031B1 (en) * 2001-11-14 2002-11-19 In Mo Hwang Pillow oriented for comfort in varying sleeping positions
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
JP4545584B2 (ja) * 2002-05-17 2010-09-15 デューク ユニバーシティ 肥満を治療するための方法
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
RU2350327C2 (ru) * 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
EP1633400A2 (en) * 2003-05-16 2006-03-15 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US7759358B2 (en) * 2003-07-23 2010-07-20 Crooks Peter A Oral bioavailable prodrugs
WO2005049043A1 (en) * 2003-11-18 2005-06-02 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising metformin and anticonvulsant agents
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US7429580B2 (en) * 2004-01-13 2008-09-30 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
JP2008509142A (ja) * 2004-08-03 2008-03-27 オレキシジェン・セラピューティクス・インコーポレーテッド 体重減少に影響を及ぼすためのブプロピオンと第２の化合物との組合せ
EP1827450A4 (en) * 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE

Also Published As

Publication number Publication date
TW200536553A (en) 2005-11-16
IL178977A0 (en) 2007-03-08
MXPA06012685A (es) 2007-01-16
CN1968692A (zh) 2007-05-23
EP1748776A1 (en) 2007-02-07
WO2005110405A1 (en) 2005-11-24
AR048771A1 (es) 2006-05-24
AU2005244151A1 (en) 2005-11-24
RU2006139930A (ru) 2008-06-10
JP2007536229A (ja) 2007-12-13
CA2565154A1 (en) 2005-11-24
US20050277579A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
BRPI0510593A (pt) composições para afetar a perda de peso
BRPI0506829A (pt) composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
TR201908551T4 (tr) Yakıt bileşimleri.
ATE541928T1 (de) Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
AR056256A1 (es) Plantas resistentes al estres
EA200900892A1 (ru) Материал и/или топливо, получаемые из биомассы
FI20021596L (fi) Dieselmoottorin polttoainekoostumus
AR068275A1 (es) Composiciones de combustibles
EP2183084A4 (en) SAW CHAIN FOR CUTTING AGGREGATES
AR082343A2 (es) Un metodo de reduccion de desgaste por rozamiento para combustibles y procedimiento para preparar una composicion combustible
BR0103736A (pt) Uso de uma composição que compreende pelo menos um composto metalo-orgânico e processo de tratamento das matérias queratìnicas
BR0317229A (pt) Composição e uso de agonista completo de alfa7nachr
ATE512998T1 (de) Verbesserte phthalonitril-verbundwerkstoffe
BR0104989A (pt) Aço estrutural para usinagem superior em descartabilidade de cavacos e propriedades mecânicas e processo para produzir um aço estrutural para usinagem
BRPI0406188A (pt) Método e dispositivo para transferência de eco-valores
BRPI0502534A (pt) Gel perfluoroelastomérico, processo para formar géis perfluoroelastoméricos, perfluoroelastÈmeros reticuláveis e curados, artigos manufaturados, e, uso de gel
BRPI0502508A (pt) Gel fluoroelastomérico, processo para formar géis fluoroelastoméricos, fluoroelastÈmeros reticuláveis e curados, artigos manufaturados, e, uso de gel
Arai Interfacial fracture toughness evaluation of ceramic thermal barrier coatings based on indentation test method
BRPI0508849A (pt) composições de alimentos para animais de estimação contendo uma fonte adicional de boro
Hu et al. Effect of fuel supply advance angle on combustion and emission of diesel engines fuelled with diesel/methanol blend
BRPI0417542A (pt) uso de chp como um inibidor de glutationa s-transferases e colágeno iv
BR0306730A (pt) Processo e intermediários para agentes antidiabéticos de piridazinona
BR0316949A (pt) 2-oxiamino-1-ciclopenteno-1-nitrilas como agentes protetores de materiais
Shang et al. Research on the effect of forced swirl combustion chamber on air-fuel mixture process in diesel engine
Bai et al. Study on emission optimization applying genetic algorithms in diesel engines

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]